Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

Cell therapy, one of the most promising frontiers in modern medicine, holds the potential to cure once-incurable diseases such as cancer and genetic disorders. But for all its promise, manufacturing ...

Ahead of his talk at the 7th Annual Allogeneic Cell Therapies Summit, Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale ...

A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor (CAR) T cells, including how they evolve during manufacturing and ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

Collaboration builds on CAR-T commercialization in New Zealand and supports expansion across Australia, North America and other international markets.Wellington, New Zealand and Kingston, ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

Building on validated HIP technology, Sana Biotechnology is advancing SC451, a stem cell-derived therapy designed as a one-time treatment targeting normal blood glucose without exogenous insulin or ...

In this innovation spotlight, Tia Harmon, technical science liaison, CGT for PHC Corporation of North America (PHCNA), discusses the key challenges in CGT manufacturing and how in-line monitoring ...